Cell Therapeutics to submit supplemental filing for Zevalin

09/22/2008 | MarketWatch

Cell Therapeutics is planning to submit later this year a supplemental Biologics License Application that proposes a label expansion for the use of Zevalin as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma. The company, following a meeting with the FDA, said the First-Line Indolent Trial results of Zevalin are sufficient to support the sBLA.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Director of Litigation
Center for Science in the Public Interest
Washington, DC
Health Plan CEO - Oregon
Trillium Community Health Plan
Eugene, OR
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC